Cargando…
Dermatomyositis following Biosimilar Trastuzumab in a Breast Cancer Patient: A Case Report
Trastuzumab, as a recombinant IgG1 kappa, is a humanized monoclonal antibody against human epidermal growth factor receptor 2. Accordingly, it is widely used in breast cancers at early and advanced stages. Dermatomyositis is a rare adverse event of trastuzumab therapy, which is not well documented y...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
S. Karger AG
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339515/ https://www.ncbi.nlm.nih.gov/pubmed/34413744 http://dx.doi.org/10.1159/000517819 |